Energy News / Shareholders Foundation, Inc.

NASDAQ:RARE Shareholder Notice: Investigation over Potential Wrongdoing at Ultragenyx Pharmaceutical Inc.

Via: ReleaseWire

Updated 11:45 AM CST, Wed, November 28,2018

An investigation on behalf of investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares over potential wrongdoing at Ultragenyx Pharmaceutical Inc. was announced

San Diego, CA -- (SBWIRE) -- 11/28/2018 -- Certain directors of Ultragenyx Pharmaceutical Inc. are under investigation over potential breaches of fiduciary duties.

Investors who purchased shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and currently hold any of those NASDAQ: RARE shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Ultragenyx Pharmaceutical officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Ultragenyx Pharmaceutical Inc. reported that its Net Loss increased from $245.87 million in 2016 to $302.13 million in 2017. Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) declined from $90.98 per share in September 2018 to as low as $46.40 per share on October 29, 2018.

The total compensation of the CEO rose from over $5.4 million in 2015 to over $6.68 million in 2017.

On November 12, 2018, NASDAQ: RARE shares closed at $49.10 per share.

Those who purchased shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqrare-shareholder-notice-investigation-over-potential-wrongdoing-at-ultragenyx-pharmaceutical-inc-1094301.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com